According to Activaero, a Phase 2 trial of a budesonide suspension delivered using its FAVORITE (Flow and Volume Controlled Inhalation Technology) system in children with mild to moderate asthma improved asthma control, reduced treatment times, and required lower doses of the drug.
In the proof-of-concept study, 41 German children aged 3 to 11 with mild to moderate asthma were treated with budesonide twice a day for 12 weeks using either the Activaero FAVORITE system or a PARI LC Sprint jet nebulizer. Delivery time was only 2 minutes for the FAVORITE system compared to the jet nebulizer, and the dose was reduced by 75% due to increased deposition in the lungs.
Activaero Founder and CEO Gerhard Scheuch commented, “We are excited about the potential of this drug-device combination to improve the treatment of children’s asthma. Usually a relatively long treatment time of 20 minutes is required in asthma therapy of young children while the therapeutic effects are often unsatisfactory. That is a problem, especially in this patient population, who are often not able to stay focused during the inhalation process. Our therapy approach has shown that with only 25% of the usual dose the drug deposition into the lung is higher, while, at the same time, treatment duration was significantly reduced to only 2 minutes. These promising results promote the further development of Activaero´s inhalation approach tailored to the special needs of children suffering from asthma.”
Read the Activaero press release.
